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Long-term outcome and its
predictors in giant
cell myocarditis. Letter
regarding the article
‘Long-term outcome and its
predictors in giant cell
myocarditis’
In 2016, we reported in your Journal1 on
the outcome of 46 patients with giant cell
myocarditis (GCM) in Finland. Later, we
encountered incidental cases of GCM where
the diagnosis was converted to cardiac
sarcoidosis (CS) at post-transplant or post-
Figure 1 An example of cardiac sarcoidosis (CS) initially mistaken for giant cell myocarditis. (A) Shows five pieces of endomyocardial tissue
acquired at the same biopsy session from a patient with atrioventricular conduction block. Two pieces look histologically normal while three
show diffuse inflammation and myocyte injury. High magnification (B) reveals small multinucleated giant cells (arrows) and numerous infiltrating
eosinophils but no epithelioid-cell granulomas. A diagnosis of giant cell myocarditis was made. (C) Demonstrates lung cryobiopsies taken later
from the same patient. Several well-formed granulomas (*) diagnostic of sarcoidosis are seen. Cardiac involvement was reclassified as cardiac
sarcoidosis.
mortem examinations. This forced us to
re-evaluate all GCM diagnoses made since
1991 in our country.2 Altogether 26 of
the 46 cases were reclassified as CS, most
commonly due to recognition, with help
of immunochemistry, of sarcoid granulo-
mas missed or misinterpreted on original
microscopy (Figure 1). The 5-year estimate
(95% confidence interval) of transplant-free
survival, having been 42% (39–56%) in our
2016 report,1 was 25% (0–40%) in the 20
patients keeping the GCM diagnosis. In Cox
regression analysis involving all 46 patients,
GCM predicted the occurrence of death
or transplantation with a hazard ratio (95%
confidence interval) of 2.68 (1.22–5.87,
P = 0.014). In bivariate Cox analyses,
biomarkers of cardiac injury and dysfunc-
tion, as well as at least moderate myocardial
necrosis or fibrosis, predicted the outcome
independent of the diagnosis of CS or GCM.
The hazard ratios are shown in Table 1.
Cardiac sarcoidosis and GCM are
known to share clinical manifestations
and characteristics of histopathology.3–5
Their differentiation on microscopy of tiny
endomyocardial samples can be very difficult,
sometimes nearly impossible. Magnetic res-
onance imaging and 18F-fluorodeoxyglucose
(18F-FDG) positron emission tomography
can be of some help as mediastinal lym-
phadenopathy and 18F-FDG uptake suggest
CS and mediastinal lymph node biopsy may
expose sarcoidosis histology. Distinction of
CS and GCM is complicated further by the
fact that researchers divide on the diagnostic
role of myocardial granulomas. Some, like
us, consider granulomas and GCM mutually
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 1 Bivariate Cox analyses
Predictor Model 1 Model 2 Model 3 Model 4
(e/n = 25/45) (e/n = 16/36) (e/n = 19/38) (e/n = 17/37)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
GCM diagnosis 2.39 (1.02–5.60)* 1.98 (0.66–5.96) 1.12 (0.37–3.36) 4.21 (1.47–12.05)**
LVEF, per +5% 0.91 (0.78–1.01) – – –
NT-proBNP, per +1000 ng/L – 1.06 (1.02–1.09)** – –
cTnT >85 ng/L (median) – – 4.28 (1.30–14.04)* –
Grade 2–3 necrosis or fibrosisa – – – 7.61 (2.38–24.39)§
The data are hazard ratios (95% confidence interval).
cTnT, cardiac troponin T; e/n, endpoint events/total numer of patients with sufficient data available for the model; GCM, giant cell myocarditis; LVEF, left ventricular ejection
fraction; NT-proBNP, N-terminal pro brain natriuretic peptide.
*P< 0.05;
**P< 0.01;
§P< 0.001.
aScale 0–3 on myocardial microscopy.
exclusive2–4 but others disagree.5 It is also
possible that CS and GCM are not fully differ-
ent entities but intimately related diseases or
even partially overlapping segments of a single
disease spectrum. The reader who favours
their dichotomy should know, however, that
the study population of our 2016 paper1
was a mix of CS and GCM by our current
criteria and that the lower 5-year survival
estimate reported here better represents
true GCM.
Kaj Ekström∗ ,
Anne Räisänen-Sokolowski,
Jukka Lehtonen, and
Markku Kupari
Heart and Lung Center, Helsinki University
Hospital, Helsinki, Finland
*Email: kaj.ekstrom@helsinki.fi
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Evaluating biomarkers as
predictors of cancer therapy
cardiotoxicity: all you need is
a meta-analysis?. Letter
regarding the article
‘Troponins and brain
natriuretic peptides for the
prediction of cardiotoxicity in
cancer patients: a
meta-analysis.’
We read with great interest the meta-analysis
by Michel et al.1 who investigated troponins
and B-type natriuretic peptides (NPs) as indi-
cators of cardiac damage and predictors of
systolic dysfunction in adult patients receiv-
ing anticancer drugs (anthracyclines, HER2
inhibitors or their combination, myeloablative
therapy for stem cell transplantation, radio-
therapy, or other chemotherapy regimens).
Herein, we would like to highlight some
possible issues with their analysis, which may
inform future research on this topic.
The literature search was done in Novem-
ber 2018. It did not include recent significant
evidence such as the study reporting that
the risk of cardiac dysfunction over 4 years
is two-fold higher when high-sensitivity tro-
ponin T (hs-TnT) is >14 ng/L at the end of
anthracycline treatment and that a doubling
of N-terminal fragment of pro-B-type NP
during therapy is associated with a 1.6-fold
higher risk of cardiac dysfunction.2 Similarly,
the Authors did not consider a novel and
promising field of research, namely troponins
as indicators of myocarditis by immune
checkpoint inhibitors.3 Furthermore, the
whole analysis revolved around a comparison
between normal and elevated troponin levels,
but we are not entirely convinced of the
opportunity to pool together troponin T and
I assays of different generations, with highly
different upper reference values (e.g. 14 ng/L
for hs-TnT and 80 ng/L for troponin I with
the I-STAT assay).4 We may add that reducing
plasma troponin values to a binary variable
(elevated vs. normal) is likely to underexploit
the information conveyed by a troponin
dosage. Troponin increase from baseline to
the end of treatment might further refine
prognostic stratification, also because high-
sensitivity assays have a low intra-individual
coefficient of variation, which means that
random fluctuations are small. Troponin lev-
els are reliably associated with the severity of
ongoing myocardial damage.5 Finally, reduced
left ventricular ejection fraction is only a
surrogate endpoint, and biomarkers should
be preferably evaluated as predictors of more
clinically robust outcome measures, such as
heart failure hospitalization or cardiovascular
mortality.
In summary, Michel et al. should be con-
gratulated for their effort to provide a
synthetic assessment of the sparse and het-
erogeneous evidence on troponins and NPs
as indicators and predictors of cardiotoxicity.
Nonetheless, their analysis is burdened by
some limitations that could be overcome only
by pooling together individual patient data,
or by designing prospective studies aiming to
answer specific questions.
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